To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase II study, titled 'A Single-Arm, Open-Label Phase II Clinical Trial to Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined with NBB-001 and NBB-002 for Patients with Recurrent Head and Neck Malignancies.', aims to assess the efficacy and safety of BNCT in patients with Recurrent Head and Neck Malignancies. Primary Objective: To evaluate the efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent head and neck malignancies.Secondary Objectives:To evaluate the efficacy of BNCT in patients with recurrent head and neck malignancies based on secondary efficacy endpoints;To characterize the pharmacokinetic (PK) profiles and radiation dosimetric characteristics of NBB-002 in patients with recurrent head and neck malignancies;To evaluate the safety of BNCT in patients with recurrent head and neck malignancies;To evaluate the equipment performance and equipment deficiencies of the boron neutron capture therapy system.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18–75 lat
- •Potwierdzony rak głowy lub szyi
- •Nowotwór wrócił po poprzednim leczeniu lub pacjent nie toleruje standardowych metod
- •Co najmniej jedno zmieralne ognisko nowotworu
- •Bor gromadzi się w guzie (badanie PET/CT pokazuje stosunek ≥2,5)
- •Niezbędne zdolności funkcjonalne nerek, wątroby i krwi
- •Oczekiwana długość życia minimum 3 miesiące
- •Poprzednie działania niepożądane po terapii powinny ustąpić
✗ Disqualifies
- •Alergia na składniki leku lub ciężkie alergie w przeszłości
- •Wielokrotny jednoczesny nowotwór
- •Przerzuty nowotworu w wielu oddalonych miejscach
- •Ryzyko poważnego krwawienia z naczyń bez możliwości zapobiegania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Xiamen Humanity Hospital
Xiamen, China
Trial contact
Jianji Pan
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.